3-FEA: Difference between revisions - PsychonautWiki Archive

Line 90:

==Toxicity and harm potential==

The toxicity and long-term health effects of recreational 3-FEA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because 3-FEA has an extremely brief history of human usage, first becoming available in mid-2016. Early anecdotal reports from people within the community who have tried 3-FEA suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it very cautiously sparingly (although nothing can be completely guaranteed).

The toxicity and long-term health effects of recreational 3-FEA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because 3-FEA has an extremely brief history of human usage, first becoming available in mid-2016.

~~===Potential cardiotoxicity===~~

Early anecdotal reports suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it very cautiously sparingly (although nothing can be completely guaranteed).

Due to its [[serotonin]]-releasing [[entactogenic]] properties, it is possible 3-FEA may display significant affinity and activity at the 5-HT<sub>2B</sub> receptor, which like 5-HT<sub>2B</sub> agonists such as [[MDMA]] and fenfluramine would make it cardiotoxic with long-term or heavy use.'''<ref>Huang, X. P., Setola, V., Yadav, P. N., Allen, J. A., Rogan, S. C., Hanson, B. J., ... & Roth, B. L. (2009). Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. ''Molecular Pharmacology'', 76(4), 710-722. https://doi.org/10.1161/01.CIR.102.23.2836</ref>

@@ Line 90: / Line 90: @@
 ==Toxicity and harm potential==
 {{Further|Research chemicals#Toxicity and harm potential}}
-The toxicity and long-term health effects of recreational 3-FEA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because 3-FEA has an extremely brief history of human usage, first becoming available in mid-2016. Early anecdotal reports from people within the community who have tried 3-FEA suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it very cautiously sparingly (although nothing can be completely guaranteed).
+The toxicity and long-term health effects of recreational 3-FEA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because 3-FEA has an extremely brief history of human usage, first becoming available in mid-2016.
-===Potential cardiotoxicity===
+Early anecdotal reports suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it very cautiously sparingly (although nothing can be completely guaranteed).
 Due to its [[serotonin]]-releasing [[entactogenic]] properties, it is possible 3-FEA may display significant affinity and activity at the 5-HT<sub>2B</sub> receptor, which like 5-HT<sub>2B</sub> agonists such as [[MDMA]] and fenfluramine would make it cardiotoxic with long-term or heavy use.'''<ref>Huang, X. P., Setola, V., Yadav, P. N., Allen, J. A., Rogan, S. C., Hanson, B. J., ... & Roth, B. L. (2009). Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. ''Molecular Pharmacology'', 76(4), 710-722. https://doi.org/10.1161/01.CIR.102.23.2836</ref>